Playing "kick the FDA" - Risk-free to players but hazardous to public health

New England Journal of Medicine

Volumn 358, Issue 17, 2008, Pages 1774-1775

  Wood, Alastair J J ^a,b,c  

^a Pharmaceutical Research and Manufacturers of America   (United States)

^b Sapphire Therapeutics

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; HEPARIN; MELAMINE; ROFECOXIB;

CHINA; DEVICE; DRUG FATALITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FOOD SAFETY; FUNDING; HEALTH HAZARD; HUMAN; INFORMATION TECHNOLOGY; PHARMACEUTICAL CARE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY CONTROL; RISK ASSESSMENT; SHORT SURVEY; TOBACCO INDUSTRY; UNSPECIFIED SIDE EFFECT;

EID: 42549096210     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp0802227     Document Type: Article

References (3)

1. FDA science and mission at risk: report of the Subcommittee on Science and Technology. Rockville, MD: Food and Drug Administration, November 2007.
2. Senators clash over "Bridge to Nowhere." Seattle Times. October 21, 2005.
3. Mathews AW, Burton TM. FDA identifies contaminant in heparin batches. Wall Street Journal. March 20, 2008:A4.